CSA Medical completes treatments in the RejuvenAir Safety and Feasibility Study for Chronic Bronchitis patients

CSA medical declared the completion of the treatment phase for its ongoing study The Safety and Feasibility Study of RejuvenAir for Treating Chronic Bronchitis Patients (NCT02483637). Open-label, single arm study of COPD patients with known chronic bronchitis is being conducted at three sites in the NetherlandsUnited Kingdom, and Canada.

The study strongly advocates the feasibility of using Liquid Nitrogen Metered Cryospray (MCS) throughout the central airways to ablate inflamed bronchial epithelium allowing non-inflamed tissue to regenerate after treatment.

The Netherlands by Dr. Dirk-Jan Slebos, M.D., PhD of the Department of Pulmonary Diseases, who reported that “The Liquid Nitrogen Metered Cryospray therapy is very well tolerated by our patients and appears to have a beneficial response with a decrease in their cough and mucus production as well as an improvement in breathing, resulting in increased physical activity.”

The study of 35 patients that were completed incorporating treatment without device related adverse events. Chronic Bronchitis is the largest disease subset of Chronic Obstructive Pulmonary Disease (COPD). Bronchitis is inflammation of the bronchial airways. A chronic bronchitis diagnosis is defined by cough with productive sputum of three months duration for two consecutive years.

Comments (0)
Add Comment